Medigene AG maintains revenue guidance for the fiscal year 2022. For the period, the company continues to expect revenues of EUR 23 million to EUR 28 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.2 EUR | -1.23% | -1.64% | -21.31% |
05-21 | Medigene, BioNTech Extend Cancer Immunotherapy Partnership | MT |
05-21 | Medigene AG's Global Research & Collaboration Agreement with BioNTech SE to Extend Beyond Initial Announced Term | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.31% | 38.36M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- MDG1 Stock
- News Medigene AG
- Medigene AG Maintains Revenue Guidance for the Fiscal Year 2022